Key Points
- Insider sale: VP David Foehr sold 5,556 shares on Feb. 3 at $20 for $111,120, reducing his stake by 22.72% to 18,900 shares; he also sold 5,556 shares on Jan. 5 and 5,265 on Dec. 3, totaling 16,377 shares for about $325,296 in proceeds.
- Stock and fundamentals: CeriBell shares last traded at $18.95 with a market cap of $702.9M, negative earnings (analyst consensus -2.46 EPS this year) and a negative net margin of 63.35%, with 50-/200-day moving averages of $21.10 and $15.65 respectively.
- Analyst view: The consensus rating is a Moderate Buy with an average price target of $24.67 (ratings include 1 Strong Buy, 5 Buy and 1 Sell), while individual targets range roughly $17–$30.
CeriBell, Inc. (NASDAQ:CBLL - Get Free Report) VP David Foehr sold 5,556 shares of CeriBell stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $20.00, for a total transaction of $111,120.00. Following the completion of the sale, the vice president directly owned 18,900 shares of the company's stock, valued at approximately $378,000. This trade represents a 22.72% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
David Foehr also recently made the following trade(s):
- On Monday, January 5th, David Foehr sold 5,556 shares of CeriBell stock. The stock was sold at an average price of $22.60, for a total transaction of $125,565.60.
- On Wednesday, December 3rd, David Foehr sold 5,265 shares of CeriBell stock. The stock was sold at an average price of $16.83, for a total value of $88,609.95.
CeriBell Price Performance
Shares of CeriBell stock traded down $0.39 during trading hours on Friday, reaching $18.95. The company's stock had a trading volume of 6,490 shares, compared to its average volume of 358,838. CeriBell, Inc. has a one year low of $10.01 and a one year high of $26.04. The company has a debt-to-equity ratio of 0.12, a current ratio of 12.65 and a quick ratio of 12.25. The firm has a 50 day moving average price of $21.10 and a 200-day moving average price of $15.65. The stock has a market cap of $702.90 million, a P/E ratio of -12.58 and a beta of 1.03.
CeriBell (NASDAQ:CBLL - Get Free Report) last posted its quarterly earnings data on Tuesday, November 4th. The company reported ($0.37) earnings per share for the quarter, beating analysts' consensus estimates of ($0.43) by $0.06. The business had revenue of $22.59 million for the quarter, compared to analysts' expectations of $21.78 million. CeriBell had a negative net margin of 63.35% and a negative return on equity of 29.63%. On average, analysts predict that CeriBell, Inc. will post -2.46 EPS for the current year.
Institutional Trading of CeriBell
Several large investors have recently added to or reduced their stakes in CBLL. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in CeriBell during the third quarter valued at $33,000. CWM LLC increased its stake in shares of CeriBell by 1,178.5% in the 4th quarter. CWM LLC now owns 1,841 shares of the company's stock valued at $40,000 after purchasing an additional 1,697 shares in the last quarter. Tower Research Capital LLC TRC boosted its position in CeriBell by 353.8% during the second quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company's stock worth $43,000 after purchasing an additional 1,801 shares in the last quarter. Ameritas Investment Partners Inc. increased its position in shares of CeriBell by 97.5% in the second quarter. Ameritas Investment Partners Inc. now owns 2,544 shares of the company's stock valued at $48,000 after buying an additional 1,256 shares in the last quarter. Finally, Larson Financial Group LLC lifted its stake in shares of CeriBell by 1,403.1% in the fourth quarter. Larson Financial Group LLC now owns 2,871 shares of the company's stock worth $63,000 after buying an additional 2,680 shares in the last quarter.
Wall Street Analyst Weigh In
A number of brokerages recently weighed in on CBLL. BTIG Research reiterated a "buy" rating and set a $30.00 price objective on shares of CeriBell in a report on Wednesday, January 28th. TD Cowen reiterated a "buy" rating on shares of CeriBell in a research note on Tuesday, December 9th. JPMorgan Chase & Co. cut their price objective on shares of CeriBell from $21.00 to $17.00 and set an "overweight" rating on the stock in a research report on Wednesday, November 5th. Raymond James Financial started coverage on shares of CeriBell in a research note on Tuesday, October 21st. They set a "strong-buy" rating and a $19.00 price objective for the company. Finally, Canaccord Genuity Group lifted their price target on shares of CeriBell from $29.00 to $30.00 and gave the stock a "buy" rating in a report on Wednesday, December 17th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $24.67.
Read Our Latest Report on CeriBell
CeriBell Company Profile
(
Get Free Report)
CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell's solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.
The company's product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
